Meeting to review and revise WHO interim guidance on laboratory testing for zika, dengue, and chikungunya
Overview
WHO is holding a meeting at WHO Headquarters in Geneva, Switzerland on 11 October 2018 to review and revise WHO interim guidance on laboratory testing for Zika, dengue, and chikungunya. The final guidance is expected to be completed by March 2019.
Members of the public and interested organizations can view the biographies of these GDG members here. They can also inform WHO of their views concerning any of these proposed members until 25 October 2018, by writing to lackritze@who.int.
Participants at the upcoming meeting include WHO staff from headquarters, regions, and countries and technical experts from academic research and public health organizations. The meeting will review the current interim guidance and identify key areas that need update, revision, clarity, or further literature review to revise guidance based on the best available scientific evidence, that are relevant for use by all WHO member states.
The meeting is funded by USAID and the World Health Organization.
Disclaimer
In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/normative advice, the names and brief biographies of individuals (“Published Information”) being considered for participation in a WHO-convened meeting to review and revise Zika, dengue, and chikungunya interim laboratory guidance are disclosed for public notice and comment.
The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.
The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO’s conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.
Participants in the meeting to review and revise WHO interim guidance on dengue, Zika, and chikungunya laboratory guidance provide technical review and comment to WHO. Participation in the meeting convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO.
The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, will be reported publicly in accordance with WHO policies.